---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-056198"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2026-08-12T20:12:27+00:00"
generated_at: "2026-08-12T20:13:06.012380+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Allogene Q2 2026: Cema-Cel MRD clearance 58.3% vs 16.7%; FDA grants RMAT and Fast Track

## Summary
- Cema-Cel ALPHA3 interim analysis: 58.3% (7/12) MRD-negative vs 16.7% (2/12) observation; 41.6% absolute difference.
- FDA granted RMAT and Fast Track designations for cema-cel as 1L LBCL consolidation after interim futility review.
- Site activations accelerated: >80 sites six months early; ~100 sites expected by year-end 2026; enrollment complete by YE2027.
- Q2 2026 net loss $42.7M ($0.13/share); cash $423.6M, runway into 2029; 2026 GAAP opex ~$225M.
- ALLO-329 RESOLUTION trial enrolling briskly; clinical data update expected Q4 2026.

## SEC filing metadata
- accession: 0001628280-26-056198
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2026-08-12T20:12:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/0001628280-26-056198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000162828026056198/allo-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-056198
- JSON: https://secwatch.observer/filing/0001628280-26-056198.json
- Plain text: https://secwatch.observer/filing/0001628280-26-056198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.